Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00090246 | 2 Doses of an Approved Drug Being Studied for a New Indication for the Prevention of Postoperative Nausea and Vomiting (0869-091) | PHASE3 | COMPLETED | 922 | — | — | May 13, 2004 | Apr 20, 2005 | May 5, 2017 | - | — |
| NCT00090155 | 2 Doses of an Approved Drug Being Studied for a New Indication for the Prevention of Postoperative Nausea and Vomiting (0869-090)(COMPLETED) | PHASE3 | COMPLETED | 805 | — | — | Sep 26, 2003 | Nov 24, 2004 | May 5, 2017 | - | — |
| Name | Type | Description |
|---|---|---|
| MK0869, aprepitant | DRUG | - |
| Comparator: ondansetron IV | DRUG | - |
Inclusion Criteria: * Patient is at least 18 years of age. * Patient is scheduled to undergo open abdominal surgery requiring overnight hospital stay (24-hour hospital stay after end of surgery). * Patient is scheduled to receive general anesthesia. * Patient is scheduled to receive postoperative o...